Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
10 Dec 2014 PD-1 Blockade Shows Safety and Efficacy in Pretreated Hodgkin Lymphoma Haematologic malignancies - Immuno-oncology
09 Dec 2014 FDA Approves Blinatumomab to Treat a Rare Form of Acute Lymphoblastic Leukaemia Haematologic malignancies - Immuno-oncology
05 Dec 2014 FDA Approves Ruxolitinib to Treat Patients With Polycythemia Vera Haematologic malignancies - Anticancer agents & Biologic therapy
04 Dec 2014 New WHO Guide to Prevent and Control Cervical Cancer Bioethics, legal and economic issues - Cancer prevention - Gynaecologic malignancies
27 Nov 2014 FDA Warns Against Using Laparoscopic Power Morcellators to Treat Uterine Fibroids Bioethics, legal and economic issues
26 Nov 2014 Dual or Triple Inhibition May be Better Than Monotherapy in Patients With BRAF-mutated Advanced Colorectal Cancer Gastrointestinal cancers - Anticancer agents & Biologic therapy
25 Nov 2014 Withdrawal of the Marketing Authorisation Application for Balugrastim Bioethics, legal and economic issues - Palliative and supportive care
24 Nov 2014 NICE Is Updating Its Guideline on Suspected Cancer to Help GPs Spot the Early Signs and Symptoms of Cancer Bioethics, legal and economic issues
24 Nov 2014 Immuno-Oncology 2014 Press Release: High-Dose Interleukin-2 Effective in mRCC Pre-Treated With VEGF-Targeted Therapies Immuno-oncology
21 Nov 2014 Immuno-Oncology 2014 Press Release: Immune Checkpoint Inhibitors May Work in Brain Cancer Immuno-oncology
21 Nov 2014 Immuno-Oncology 2014 Press Release: Possibilities for Personalised Vaccines Revealed at ESMO Symposium Immuno-oncology
21 Nov 2014 A Mutation Signature for Clinical Response to Immune Checkpoint Inhibitors Translational research - Melanoma - Immuno-oncology
20 Nov 2014 Immuno-Oncology 2014 Press Release: Immunotherapy Set to Revolutionise Cancer Treatment Immuno-oncology
20 Nov 2014 Patients with Advanced Papillary RCC Respond Well to a Combination of Bevacizumab and Erlotinib Genitourinary cancers - Anticancer agents & Biologic therapy
17 Nov 2014 FDA Approves Bevacizumab in Combination with Chemotherapy for Platinum Resistant, Recurrent Ovarian Cancer Gynaecologic malignancies - Anticancer agents & Biologic therapy